 Wysłany: Pią 8:08, 11 Lut 2011 Temat postu: WuXi PharmaTech Well Positioned to Continue Growin |
|
| WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that its previously announced transaction with Charles River Laboratories International Inc. (NYSE: CRL) has been terminated by mutual agreement due to Charles River shareholder opposition. Under the terms of the termination agreement, WuXi will receive a breakup fee of $30 million.
"WuXi‘s strategy has not changed. Our goal is, and has long been, to build a broad,Business process outsourcing, integrated R&D service platform designed to help our customers improve the success of research and shorten the time of new product development,hospitality solution," said Dr. Ge Li, Chairman and Chief Executive Officer. "While we are disappointed that this transaction could not be completed,Mobile solution, WuXi remains well positioned to meet our customers‘ needs and to continue to grow and expand as a standalone company. "All of our businesses are performing very well," Dr. Li continued. "Each business unit has met or exceeded its targets for the second quarter, and we recently increased our guidance for full-year 2010 financial performance. "Virtually all of the large global pharmaceutical companies, as well as hundreds of smaller pharmaceutical and biotech companies and many leading medical device companies,Help desk outsourcing, are our customers," Dr. Li concluded. "We believe that strong trends for greater outsourcing and offshoring of R&D services will continue, and that WuXi, as the leading China-based contract research organization, is well positioned to benefit from this powerful outsourcing trend for many years to come." Second Quarter Results WuXi will report financial results for the second quarter ending June 30,health care outsourcing, 2010, on Monday, August 2, at 6:30 am EDT with a conference call at 8:30 am EDT to discuss the results and the outlook for WuXi‘s business. The conference call may be accessed by calling: United States: 1-866-519-4004 China (Landline): 800-819-0121 China (Mobile): 400-620-8038 Hong Kong: 800-930-346 United Kingdom: 0-808-234-6646 International: +65-6723-9381 Conference ID: 90840146 Web PIN: 8656 A replay will be available two hours after the call‘s completion at: United States: 1-866-214-5335 China North: 10-800-714-0386 China South: 10-800-140-0386 Hong Kong: 800-901-596 United Kingdom: 0-800-731-7846 International: +61-2-8235-5000 Passcode: 90840146 A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech‘s website at . |
|
